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89 
CANNABIS CONSIDERATIONS FOR 
HEALTH CARE ENTITIES 
VANESSA K. BURROWS* 
I.  INTRODUCTION 
This article provides a brief overview of key federal laws that address 
marijuana and hemp and considerations for health care facilities and providers 
with respect to cannabis use by patients, compliance with Medicare Conditions 
of Participation, and research.1  While many states in the U.S. permit the 
cultivation, distribution, and sale of marijuana, federal laws and guidance 
generally do not permit such activities.2  Federal laws have limited exceptions, 
such as exceptions for the cultivation of marijuana that will be used in federally-
sanctioned research.3  Federal law also permits the sale of certain drugs approved 
by the Food and Drug Administration (“FDA”) that contain active ingredients 
that are present in botanical marijuana or that are synthetic versions of 
components in botanical marijuana.4  Though an increasing number of states 
have changed their laws to license recreational and medical marijuana businesses 
or allow cultivation for personal use, marijuana remains a Schedule I controlled 
substance under the federal Controlled Substances Act (“CSA”).5  As a result, 
 
© 2021 Vanessa K. Burrows 
* Vanessa K. Burrows, J.D., M.A., advises health care providers, biopharmaceutical 
and medical device manufacturers, and healthcare technology companies in 
connection with regulatory and compliance matters, mergers and acquisitions, and 
capital-raising transactions. The views and opinions expressed in this article are 
those of the author only. 
 1. In order to distinguish the parts and types of cannabis plants that are legal under federal law 
from the parts and types of cannabis plants that are not, this article will generally refer to marijuana in 
accordance with its federal definition, rather than cannabis. 
 2. Present day state laws and initiatives vary widely, and address topics as diverse as medical uses 
of marijuana, a health care provider’s financial interest in a licensed marijuana dispensary, recreational 
or “adult use” of marijuana, health insurance coverage and exclusions for medical use of marijuana, 
workers’ compensation fee schedules for medical cannabis, workers’ compensation benefits if an 
employee’s injury occurred while the employee was under the influence of marijuana, discrimination 
against employees or job applicants who use medical marijuana in accordance with state laws, 
workplace accommodations (or a lack thereof) for medical use of marijuana, employers’ abilities to 
restrict marijuana use, drug testing, drugged driving, and, before the enactment of the Agriculture 
Improvement Act of 2018 (“2018 Farm Bill”), access to cannabidiol (“CBD”). 
 3. See infra note 98 and accompanying text. 
 4. See infra note 57 and accompanying text. 
 5. Controlled Substance Act, 21 U.S.C. § 812. 
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distributing or dispensing marijuana, or possessing marijuana with the intent to 
distribute or dispense the drug, is against federal law.6  Health care facilities and 
providers should weigh the potential consequences associated with violations of 
federal law when faced with questions about state-sanctioned activities. 
II. STATUS OF CANNABIS AND CANNABINOIDS UNDER FEDERAL LAWS, 
REGULATIONS, AND GUIDANCE 
This section discusses the key federal laws, regulations, and guidance 
documents that provide the framework for federal control over cannabis and 
cannabis products, including food, dietary supplements, cosmetics, and FDA-
approved drugs.7  This section first explains the distinction between marijuana 
and hemp.  The section then discusses the status of cannabis under federal laws, 
including the CSA, federal appropriations restrictions, the Federal Food, Drug, 
and Cosmetic Act (“FDCA”), and guidance from the Department of Justice 
(“DOJ”).  
A. Federal Definitions of Marijuana and Hemp 
In recent years, Congress has bifurcated federal oversight of cannabis into 
separate regulatory schemes for marijuana and hemp, based on the concentration 
of delta-9 tetrahydrocannabinol (“THC”).  Legislative changes began with the 
Agricultural Act of 2014 (“2014 Farm Bill”)8, which created a definition of 
“industrial hemp”: The Cannabis sativa L. plant or any part of the plant with a 
delta-9 THC concentration of not more than 0.3 percent on a dry weight basis.9 
The 2014 Farm Bill permitted limited research activities to be conducted on 
industrial hemp.10  The law also regulated the growing and cultivating of 
industrial hemp by institutions of higher education and state departments of 
agriculture if the industrial hemp was grown or cultivated for research purposes 
in states that legalized such production.11  Federal law would have otherwise 
criminalized growing and cultivation, because industrial hemp contains THC, a 
Schedule I controlled substance.12  The 2014 Farm Bill did not legalize 
 
 6. Id. 
 7. This article does not address the import and export of controlled substances. 
 8. Pub. L. No. 113-79. 
 9. 7 U.S.C. § 5940.  This definition will be repealed effective September 30, 2021. 
 10. Id. 
 11. Id. 
 12. Guidance issued by FDA, U.S. Department of Agriculture, and the Drug Enforcement 
Administration (“DEA”) states that only (1) institutions of higher education; (2) persons employed by or 
under a production contract or lease with such institutions; (3) state agriculture departments; and (4) 
persons licensed, registered or otherwise authorized by state agricultural departments to conduct 
research were permitted to conduct research on industrial hemp under the agricultural pilot programs 
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distribution of industrial hemp across state lines, and it was and still is a violation 
of the CSA to distribute a controlled substance.13  The 2014 Farm Bill also did 
not exempt industrial hemp from the CSA’s definition of marijuana.   
Until the enactment of the Agriculture Improvement Act of 2018 (“2018 
Farm Bill”) four years later on December 20, 2018, the CSA defined marijuana 
(spelled with a “h” in the statute instead of a “j”) as follows: 
 
The term “marihuana” means all parts of the plant Cannabis sativa L., 
whether growing or not; the seeds thereof; the resin extracted from 
any part of such plant; and every compound, manufacture, salt, 
derivative, mixture, or preparation of such plant, its seeds or resin. 
Such term does not include the mature stalks of such plant, fiber 
produced from such stalks, oil or cake made from the seeds of such 
plant, any other compound, manufacture, salt, derivative, mixture, or 
preparation of such mature stalks (except the resin extracted 
therefrom), fiber, oil, or cake, or the sterilized seed of such plant which 
is incapable of germination.14   
 
The 2018 Farm Bill amended the CSA’s definition of “marihuana” to exclude 
hemp, as indicated by the italicized text:  
 
[T]he term “marihuana” means all parts of the plant Cannabis sativa 
L., whether growing or not; the seeds thereof; the resin extracted from 
any part of such plant; and every compound, manufacture, salt, 
derivative, mixture, or preparation of such plant, its seeds or resin.  []  
The term “marihuana” does not include – (i) hemp, as defined in [7 
U.S.C. § 1639o]; or (ii) the mature stalks of such plant,  . . .15   
 
The 2018 Farm Bill also amended the listing of THC in Schedule I to 
exclude THC in hemp and created a new definition of “hemp” that is similar to 
the 2014 Farm Bill’s definition of industrial hemp.16  Hemp is limited to the 
cannabis plant and its seeds, derivatives, extracts, cannabinoids, isomers, acids, 
salts, and salts of isomers with a delta-9 THC concentration of not more than 0.3 
percent on a dry weight basis.17  As a result, the 2018 Farm Bill excluded 
 
authorized by the 2014 Farm Bill.  Statement of Principles on Industrial Hemp, 81 Fed. Reg. 53395 
(Aug. 12, 2016). 
 13. 21 U.S.C. § 841(a)(1) (2018). 
 14. Id. § 802(16). 
 15. Agriculture Improvement Act of 2018, Pub. L. No. 115-334, 132 Stat. 5018 (emphasis added). 
 16. Pub. L. No. 115-334, § 10113, 132 Stat. 4908. 
 17. 7 U.S.C. § 1639o(1) (2018). 
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cannabinoids, such as cannabidiol (“CBD”), with very low concentrations of the 
psychoactive component delta-9 THC from the CSA’s definition of marijuana.18 
Though hemp is no longer a Schedule I controlled substance, any cannabis-
derived product that exceeds the 0.3 percent delta-9 THC concentration still falls 
within Schedule I.19  Additionally, products derived from hemp plants that 
exceed the 0.3 percent delta-9 THC limits are considered marijuana.20 
B. The Controlled Substances Act and Drug Enforcement Administration 
(“DEA”) Regulations 
The CSA regulates the manufacture, possession, use, and distribution of 
certain drugs, substances, and precursor chemicals.21  Under the CSA, substances 
are classified into five schedules (I-V); Schedule I is the most restrictive, and 
Schedule V is the least restrictive.22  The Attorney General evaluates drugs and 
other substances for placement on one of the five schedules based on eight 
factors, including whether current scientific knowledge indicates that marijuana 
has a “currently accepted medical use,” the current pattern of abuse, and the risk 
to the public health.23  In order to be placed on Schedule I, the following findings 
are required: (1)  The drug or other substance has a high potential for abuse; (2) 
The drug or other substance has no currently accepted medical use in treatment 
in the United States; and (3)  There is a lack of accepted safety for use of the drug 
or other substance under medical supervision.24   
 
 18. Hemp Production and the 2018 Farm Bill Hearing on the 2018 Farm Bill Before the Senate 
Committee on Agriculture, Nutrition, and Forestry, FOOD & DRUG ADMIN. (2019), 
https://www.fda.gov/news-events/congressional-testimony/hemp-production-and-2018-farm-bill-
07252019 (providing testimony before 116th Congress of Amy Abernethy, MD, PhD, Principal Deputy 
Commissioner, Office of the Commissioner, FDA). 
 19. 21 U.S.C. § 812. 
 20. Implementation of the Agriculture Improvement Act of 2018, Interim Final Rule, 85 Fed. Reg. 
51639, 51641 (Aug. 21, 2020) (to be codified at 21 C.F.R. pts. 1308, 1312). 
 21. See Comprehensive Drug Abuse Prevention and Control Act of 1970, Title II, Pub. L. No. 91-
513, 84 Stat. 1242. 
 22. 21 U.S.C. § 812. 
 23. 21 U.S.C. § 811(c).  The eight factors are: (1) Actual or relative potential for abuse. (2) Known 
scientific evidence of pharmacological effects. (3) Current scientific knowledge of the drug or 
substance. (4) History and current pattern of abuse. (5) Scope, duration, and significance of abuse. (6)
Risk to public health. (7) Psychic or physiological dependence liability. (8) Whether the substance is an 
immediate precursor of an already scheduled substance.  Id. 
 24. 21 U.S.C. § 812(b)(1). 
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Marijuana and THC (except THC in hemp25) are classified as Schedule I 
controlled substances.26  The list of Schedule I controlled substances also 
includes heroin, lysergic acid diethylamide (“LSD”), and 3,4-
methylenedioxymethamphetamine (ecstasy).27  DEA regulations also list certain 
marijuana extracts as Schedule I controlled substances.28  DEA issued guidance 
on its marijuana extract rule before the 2018 Farm Bill explaining that the rule 
did not include materials or products that are excluded from the CSA’s definition 
of marijuana, such as fiber produced from mature stalks of the plant.29  In 2020, 
DEA updated the marijuana extract rule via an interim final rule that incorporated 
changes made by the 2018 Farm Bill and decontrolled hemp and hemp extracts.  
The interim final rule defined a “marijuana extract” in part as an extract 
“containing one or more cannabinoids that has been derived from any plant of 
the genus Cannabis, containing greater than 0.3 percent delta-9 [THC] on a dry 
weight basis.”30  As a result, hemp and hemp-derived extracts with less than 0.3 
percent delta-9 THC no longer fall within the revised definition of a marijuana 
extract.31 
DEA has evaluated several petitions to reschedule marijuana from Schedule 
I into a different schedule.  For example, in 2016, DEA denied a petition to 
initiate rulemaking proceedings to reschedule marijuana.32  DEA determined that 
there was no currently accepted medical use of marijuana.33  The denial of the 
petition explained:  
 
In short, marijuana continues to meet the criteria for Schedule I control 
under the CSA because: . . . Marijuana has no currently accepted 
medical use in treatment in the United States. Based on the established 
 
 25. The 2018 Farm Bill also excluded THC in hemp from Schedule I of the CSA.  Agriculture 
Improvement Act of 2018, Pub. L. No. 115-334, § 12619(b) (codified at 21 U.S.C.§ 812(c)(17)).  The 
DEA had previously said that if a product contained even a trace amount of THC, it was a controlled 
substance under Schedule I.  21 U.S.C. § 811(g); 68 Fed. Reg. 14119, 14124 (Mar. 21, 2003). 
 26. 21 U.S.C. § 812(c)(10), (17) (“Unless specifically excepted or unless listed in another schedule, 
any material, compound, mixture, or preparation, which contains any quantity of the following 
hallucinogenic substances  . . .  (10) Marihuana . . .  (17) Tetrahydrocannabinols, except for 
tetrahydrocannabinols in hemp (as defined under section 1639o of title 7).”). 
 27. 21 U.S.C. § 812(c); 21 C.F.R. § 1308.11 (2020). 
 28. 21 C.F.R. § 1308.11(d)(23), (31), (58) (2020); 85 Fed. Reg. at 51641. 
 29. Clarification of the New Drug Code (7350) for Marijuana Extract, U.S. DEP’T OF JUST.; DRUG 
ENF’T ADMIN.; DIVERSION CONTROL DIV., 
https://www.deadiversion.usdoj.gov/schedules/marijuana/m_extract_7350.html (last accessed Mar. 3, 
2021). 
 30. 21 C.F.R. § 1308.11(d)(58) (2020); 85 Fed. Reg. at 51641. 
 31. 21 C.F.R. § 1308.11(d)(58) (2020). 
 32. Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 81 Fed. Reg. 53688 (Aug. 
12, 2016). 
 33. Id. 
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five-part test for making such determination, marijuana has no 
‘currently accepted medical use’ because: As detailed in the HHS 
evaluation, the drug’s chemistry is not known and reproducible; there 
are no adequate safety studies; there are no adequate and well 
controlled studies proving efficacy; the drug is not accepted by 
qualified experts; and the scientific evidence is not widely available.34   
 
While marijuana is classified as Schedule I, DEA has scheduled other FDA-
approved drugs that contain THC or CBD into other schedules because they have 
currently accepted medical uses in treatment in the U.S.  For example, DEA 
classified an FDA-approved oral solution containing dronabinol, a synthetic 
THC, into Schedule II, which is for drugs that have a high potential for abuse 
and for which abuse may lead to severe psychological or physical dependence.35  
DEA classified a gelatin capsule version of synthetic dronabinol into Schedule 
III, which is for drugs with a potential for abuse less than the drugs in Schedules 
I and II and for which abuse may lead to moderate or low physical dependence 
or high psychological dependence.36  Both dronabinol drugs are indicated for the 
treatment of anorexia associated with weight loss in adult patients with AIDS 
and nausea and vomiting associated with cancer chemotherapy in certain patients 
who failed to respond to conventional treatments.37 
After FDA approved the CBD drug Epidiolex in 2018 for treatment of 
seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in 
patients two and older, the DEA placed FDA-approved CBD drugs that contain 
no more than 0.1 percent THC into Schedule V.38  Schedule V drugs have a low 
potential for abuse relative to drugs in Schedule IV and are drugs for which abuse 
may lead to limited physical dependence or psychological dependence relative 
to drugs in Schedule IV.39  Since FDA’s approval occurred before the enactment 
of the 2018 Farm Bill, the CBD that was the active ingredient in the drug was 
then considered an ingredient derived from marijuana.40  The Schedule V 
 
 34. Id. 
 35. 21 C.F.R. § 1308.12(f)(2) (2020). 
 36. Id. § 1308.13(g)(1). 
 37. See, e.g., Highlights of Prescribing Information SYNDROS (Dronabinol) Oral Solution, CX, 
FDA 1, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205525s000lbl.pdf (last accessed 
Mar. 3, 2021). 
 38. Press Release, FDA, FDA Approves First Drug Comprised of an Active Ingredient Derived 
from Marijuana to Treat Rare, Severe Forms of Epilepsy (June 25, 2018), https://www.fda.gov/news-
events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-
treat-rare-severe-forms; Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-
Approved Drugs Containing Cannabidiol; Corresponding Change to Permit Requirements, 83 Fed. Reg. 
48950, 48951 (Sept. 28, 2018) (to be codified at 21 C.F.R. pts. 1308, 1312). 
 39. 21 U.S.C. § 812(b)(5). 
 40. 83 Fed. Reg. at 48951. 
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regulation was specific to Epidiolex and did not include any non-FDA-approved 
CBD products.41  DEA recently removed Epidiolex from Schedule V in the same 
interim final rule that decontrolled hemp and hemp extracts, because under the 
2018 Farm Bill, the FDA-approved CBD drug is no longer considered a 
controlled substance.42  
C. Restrictions in Appropriations Laws and Related Signing Statements 
Members of the 117th Congress have introduced several bills that would 
reschedule marijuana under the CSA and are likely to continue to place 
restrictions on enforcement of marijuana laws in federal appropriations 
legislation.  Broader legislative efforts related to sweeping regulatory changes 
for marijuana, such as legalization, are likely to face an uphill battle with an 
evenly divided Senate.43  Congress may consider small-scale reforms tied to 
racial justice efforts, which could potentially garner support from President 
Biden, who has already signed executive orders focused on racial equity.44  
President Biden has previously expressed support for decriminalization.45   
Members of Congress have incorporated several restrictions on 
enforcement of marijuana laws in appropriations legislation in past years.46  Such 
restrictions attempt to limit how the DOJ, DEA, and U.S. Department of 
Agriculture can spend funds with respect to state laws on medical marijuana and 
federal pilot programs on industrial hemp.47  For example, the Consolidated 
Appropriations Act, 2021, which provides appropriations for certain federal 
agencies through September 30, 2021, explains that the DOJ may not use any 
funds made available under the law to prevent certain listed states and territories 
from implementing their own laws that authorize the use, distribution, 
 
 41. “A drug product in finished dosage formulation that has been approved by the U.S. Food and 
Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-
yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual 
tetrahydrocannabinols.” 83 Fed. Reg. at 48952–53. 
 42. Implementation of the Agriculture Improvement Act of 2018, 85 Fed. Reg. 51639, 51640 (Aug. 
21, 2020) (to be codified at 21 C.F.R. pts. 1308, 1312). 
 43. See, e.g., H.R. 365, 117th Cong. (2021) (rescheduling marijuana from schedule I to schedule 
III). 
 44.  Advancing Racial Equity and Support for Underserved Communities Through the Federal 
Government, Exec. Order No. 13985, 86 Fed. Reg. 7009 (Jan. 20, 2021). 
 45. Tim Craig, Biden, Once a Warrior in the ‘War on Drugs,’ May Slowly Retreat, WASH. POST 
(Jan. 11, 2021 at 8:00am EST), https://www.washingtonpost.com/politics/2021/01/11/biden-war-on-
drugs. 
 46. See, e.g., Consolidated Appropriations Act, 2020, Pub. L. No. 116-93, 133 Stat. 2431 (2019). 
 47. See, e.g., Consolidated Appropriations Act, 2021, Pub. L. No. 116-260, § 530, 134 Stat. 1182, 
1282 (2020) (prohibiting funds from being used to contravene the statute that established agricultural 
pilot programs for industrial hemp research). 
04 BURROWS (DO NOT DELETE)   8:50 AM3/7/2021 
96 JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 24:1 
 
possession, or cultivation of medical marijuana.48  While such restrictions may 
alter the enforcement efforts of these federal authorities, such restrictions do not 
alter the federal laws discussed above and therefore should not be viewed by 
health care entities as granting permission to undertake activities that may be 
permissible under state law. 
Additionally, the executive branch has challenged such restrictions.  
Former President Trump rejected the imposition of similar congressional 
restrictions on DOJ’s use of appropriated funds for marijuana enforcement in a 
signing statement on the Consolidated Appropriations Act, 2020, stating:  
 
Division B, section 531 of the Act provides that the [DOJ] may not 
use any funds made available under this Act to prevent 
implementation of medical marijuana laws by various States and 
territories. My Administration will treat this provision consistently 
with the President’s constitutional responsibility to faithfully execute 
the laws of the United States.49   
 
The actual impact of this particular signing statement is unclear, and legal 
scholars have questioned the legal effect of signing statements generally.50  That 
said, such signing statements underscore the potential enforcement risks that 
health care entities face if they rely on state medical marijuana laws. 
The signing statement echoes an earlier signing statement issued by then-
President Trump in response to the Consolidated Appropriations Act, 2018: 
“Division B, section 537 provides that the [DOJ] may not use any funds to 
prevent implementation of medical marijuana laws by various States and 
territories. I will treat this provision consistently with my constitutional 
responsibility to take care that the laws be faithfully executed.”51  That signing 
 
 48. Id.  
 49. Statement by the President, WHITEHOUSE.GOV (Dec. 20, 2019), 
https://trumpwhitehouse.archives.gov/briefings-statements/statement-by-the-president-33. 
 50. DOJ’s Office of Legal Counsel, which opines on questions of law when requested by the 
President, has stated that a “President that places the statutory law [i.e., the appropriations laws] over the 
constitutional law . . . would fail in his duty faithfully to execute the laws” if he finds a provision 
unconstitutional or if he determines that a statutory law violates the Constitution.  Presidential Signing 
Statements Under the Bush Administration: Hearing Before the House Comm. of the Judiciary, 110th 
Cong. 27 (2007) (statement of John P. Elwood, Deputy Assistant Attorney General, Office of Legal 
Counsel, DOJ).  In contrast, an American Bar Association task force on signing statements has argued 
that statements that claim to disregard part of a law that the President has signed are contrary to the rule 
of law and the constitutional system of separation of powers.  A.B.A., Task Force on Presidential 
Signing Statements and the Separation of Powers Doctrine: Recommendation, 
https://balkin.blogspot.com/aba.signing.statments.report.pdf (last accessed Mar. 3, 2021). 
 51. Statement by President Donald J. Trump on Signing H.R. 244 into Law, WHITEHOUSE.GOV 
(May 5, 2017), https://trumpwhitehouse.archives.gov/briefings-statements/statement-president-donald-j-
trump-signing-h-r-244-law/. 
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statement referred to the incorrect section of the law; Section 537 of the 
Consolidated Appropriations Act, 2018, prohibited DOJ and DEA from using 
funds in contravention of the provision in the Agricultural Act of 2014 that 
permitted institutions of higher education and state departments of agriculture to 
cultivate industrial hemp for research or state agricultural pilot programs.52  
Section 538 of the same law prohibited DOJ from using funds made available 
under that Act to prevent such states, territories, and D.C. from implementing 
their own laws related to medical marijuana.53  It is unclear why the signing 
statement did not also assert the same constitutional obligations with respect to 
the neighboring section of the law and its restrictions on DOJ’s enforcement 
ability. 
D. The Federal Food, Drug, and Cosmetic Act and the 2018 Farm Bill 
FDA considers cannabis and cannabis derivatives such as CBD to be 
unapproved new drugs.54  Under the FDCA, new drugs cannot legally be 
introduced or delivered for introduction into interstate commerce without FDA’s 
prior approval or authorization.55  The agency approves new drugs based on 
scientific data and information demonstrating the drug is safe and effective.56  
FDA has approved four drugs with active ingredients that are present in botanical 
marijuana or are synthetic versions of components in botanical marijuana.57  
There are many other cannabis products sold illegally in the marketplace that the 
FDA would consider to be unapproved new drugs, based on the claims made by 
 
 52. Consolidated Appropriations Act, 2018, Pub. L. No. 115-141, 132 Stat. 348, 444 (2018); 
Agricultural Act of 2014, 7 U.S.C. § 5940 (2018). 
 53. Consolidated Appropriations Act, 2018, Pub. L. No. 115-141, 132 Stat. 348, 444-45 (2018). 
 54. FDA and Cannabis: Research and Drug Approval Process, FDA, https://www.fda.gov/news-
events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process (last updated Oct. 01, 
2020). 
 55. 21 U.S.C. §§ 331(d), 355(a). 
 56. Id. § 355(b). 
 57. Researching the Potential Medical Benefits and Risks of Marijuana: Hearing before the 
Subcomm. on Crime and Terrorism, S. Comm. on the Judiciary, 114th Cong. (2016) (statement of 
Douglas C. Throckmorton, M.D., Deputy Director for Regulatory Programs, Center for Drug Evaluation 
and Research, FDA).  The four drugs are: (1) Marinol, which has the active ingredient: dronabinol, a 
THC.  Id.  FDA approved the drug in 1985 for the treatment of nausea and vomiting associated with 
cancer chemotherapy in patients who failed to respond adequately to conventional antiemetic treatments.  
Id.  FDA also approved the drug in 1992 for treatment of anorexia associated with weight loss in 
patients with AIDS.  Id.  (2) Syndros, which has the active ingredient dronabinol, a synthetic THC, and 
is FDA-approved for the same indications as Marinol.  Id.  (3) Cesamet, which has as an active 
ingredient the synthetic cannabinoid nabilone.  Id.  FDA approved Cesamet in 1985 for the treatment of 
nausea and vomiting associated with chemotherapy.  Id.  (4) Epidiolex, which has as the active 
ingredient purified CBD.  See supra note 38.  FDA approved Epidiolex in 2018 for the treatment of 
seizures associated with Lennox-Gastuat syndrome or Dravet syndrome in patients two and older.  See 
supra note 38. 
04 BURROWS (DO NOT DELETE)   8:50 AM3/7/2021 
98 JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 24:1 
 
such products with respect to the treatment or mitigation of certain diseases or 
conditions.    
As noted above, the 2018 Farm Bill law created a new definition of “hemp” 
that differentiates hemp from the Schedule I drug marijuana.58  Notably, the 2018 
Farm Bill did not amend the FDCA.59  FDA continues to regulate hemp-derived 
products under the agency’s existing authority.60  Though hemp is now a legal 
substance under federal law, FDA regulates the addition of cannabis and 
derivatives of cannabis (e.g., CBD or THC) to food, deems food with such 
derivatives to be adulterated, and requires agency approval of new drug 
applications for hemp-derived drug products.61  As a result, health care facilities 
and providers must exercise caution with respect to hemp-derived products and 
patient inquiries regarding their legality and potential uses.62   
FDA issued an announcement asserting its authority over cannabis and 
cannabis-derived products concurrent with the signing of the 2018 Farm Bill.63  
The statement explained that FDA will continue to treat cannabis-derived 
compounds like any other drug, food, or dietary supplement that the agency 
regulates, regardless of the source of the cannabis-derived substance, e.g., plants 
classified as hemp.64  The Commissioner’s statement also reminded the cannabis 
industry that even if the cannabis-derived substance is hemp-derived, it is 
unlawful to introduce foods that contain added CBD or THC into interstate 
commerce.65  The statement also: (1) noted that it is a violation of the FDCA to 
market CBD and THC products as dietary supplements; and (2) asserted that 
FDA will take enforcement action against companies illegally selling any 
cannabis and cannabis-derived products that put consumers at risk and that are 
marketed in violation of the FDCA.66 
 
 58. 7 U.S.C. § 1639r(c). 
 59. See id. 
 60. See id. 
 61. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD), 
FDA, https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-
derived-products-including-cannabidiol-cbd (last updated Jan. 22, 2021). 
 62. See id. 
 63. FDA, STATEMENT FROM FDA COMMISSIONER SCOTT GOTTLIEB, M.D., ON SIGNING OF THE 
AGRICULTURE IMPROVEMENT ACT AND THE AGENCY’S REGULATION OF PRODUCTS CONTAINING 
CANNABIS AND CANNABIS-DERIVED COMPOUNDS (2018), 
https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-
signing-agriculture-improvement-act-and-agencys. 
 64. Id. 
 65. Id. 
 66. Id. 
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Since at least 2015, FDA has issued warning letters to companies that 
market unapproved new drugs that allegedly contain cannabis or CBD.67  The 
warning letters typically note that the companies are making drug claims because 
the products are intended for use in the diagnosis, cure, mitigation, treatment, or 
prevention of disease.68  A company’s failure to correct FDCA violations may 
result in additional legal action, including seizures of the violative products or 
injunctions.69  
E. Department of Justice Guidance 
As of the date of this article, the Senate has not yet confirmed President 
Biden’s nominee for Attorney General, Judge Merrick Garland, and it is unclear 
how the Biden Administration will reshape DOJ marijuana enforcement policies.  
Judge Garland stated during his confirmation hearing that marijuana is a 
nonviolent crime for which individuals are being incarcerated at significantly 
different rates in different communities and that the DOJ can focus its attention 
on violent crimes as opposed to marijuana possession. 
Under the Obama Administration, the DOJ exercised restraint in enforcing 
federal drug laws against persons operating in states that legalized the growing 
of, trade in, and consumption of marijuana.70  The DOJ also issued several 
policies on federal enforcement efforts with respect to marijuana in response to 
state legalization initiatives.71   
Under the Trump Administration, Attorney General Jefferson Sessions 
repealed five of the Obama Administration’s memoranda to all U.S. Attorneys 
regarding the enforcement of federal marijuana laws.72  The repealed memoranda 
addressed various topics including a June 2011 memorandum which indicated 
the federal government would not focus its enforcement efforts on jurisdictions 
 
 67. See Warning Letters and Test Results for Cannabidiol-Related Products, FDA, 
https://www.fda.gov/news-events/public-health-focus/warning-letters-and-test-results-cannabidiol-
related-products. 
 68. See 21 U.S.C. § 321(g)(1)(B). 
 69. See, e.g., Letter from Donald D. Ashley, Dir., Office of Compliance, Ctr. for Drug Evaluation 
and Research, FDA to Patrice Romulus, Biota Biosciences LLC (April 9, 2020), 
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-
letters/biota-biosciences-llc-605164-04092020. 
 70. Memorandum from David W. Odgen, Deputy Att’y Gen. on Investigations and Prosecutions in 
States Authorizing the Medical Use of Marijuana to Selected U.S. Att’ys (Oct. 19, 2009); Memorandum 
from James M. Cole, Deputy Att’y Gen. on Guidance Regarding Marijuana Enforcement to All U.S. 
Att’ys (Aug. 29, 2013); Memorandum from James M. Cole, Att’y Gen. on Guidance Regarding 
Marijuana Related Financial Crime to All U.S. Att’ys (Feb. 14, 2014). 
 71. See infra note 73. 
 72. See Memorandum from Jefferson B. Sessions III, Att’y Gen. on Marijuana Enforcement to All 
U.S. Att’ys (Jan. 4, 2018), https://www.justice.gov/opa/pr/justice-department-issues-memo-marijuana-
enforcement (announcing the rescission of previous guidance documents regarding federal enforcement 
with respect to the cultivation, distribution, and possession of marijuana). 
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seeking to authorize marijuana for medical use by individuals with serious 
illnesses (e.g. cancer) and their caregivers.73  The Sessions memorandum enabled 
federal prosecutors to pursue marijuana enforcement based on “all relevant 
considerations,” including “federal law enforcement priorities set by the 
Attorney General; the seriousness of the crime; the deterrent effect of criminal 
prosecution; and the cumulative impact of particular crimes on the 
community.”74  The Biden Administration will likely repeal the Sessions 
memorandum and institute its own marijuana enforcement guidance. 
III. MARIJUANA USE BY PATIENTS IN HOSPITALS AND OTHER HEALTH CARE 
FACILITIES  
Hospitals, long-term care providers, and other facilities serving Medicare 
beneficiaries may face internal or external pressures to implement or change 
policies that would allow the possession or use of cannabis or recommendations 
for the use of medical marijuana.  Such pressures may arise from various sources 
including: (1) patients who have received recommendations for medical 
marijuana; (2) the family members and registered medical marijuana caregivers 
of such patients; (3) physicians who have obtained state licenses that enable them 
to recommend marijuana as a course of medical treatment for their patients; and 
(4) advocacy organizations and others.75  Since marijuana remains illegal at the 
federal level, it poses unique issues for health care facilities and providers 
seeking to accommodate such patients.  For example, physicians, non-physician 
providers with prescribing authority, and pharmacists may not have access to 
adequate data to advise patients who are taking FDA-approved medications on 
 
 73. Id.  The revoked Obama Administration policies included the following: 
(1) the October 2009 Ogden Memorandum regarding investigations and prosecutions in states 
authorizing medical use of marijuana; (2) the February 2014 memorandum regarding marijuana related 
financial crimes; and (3) the August 2013 Cole Memorandum that set forth eight enforcement priorities 
for the federal government: (a) Preventing the distribution of marijuana to minors; (b) Preventing 
revenue from the sale of marijuana from going to criminal enterprises, gangs, and cartels; (c) Preventing 
the diversion of marijuana from states where it is legal under state law in some form to other states; (d)  
Preventing state-authorized marijuana activity from being used as a cover or pretext for the trafficking 
of other illegal drugs or other illegal activity; (e) Preventing violence and the use of firearms in the 
cultivation and distribution of marijuana; (f) Preventing drugged driving and the exacerbation of other 
adverse public health consequences associated with marijuana use; (g) Preventing the growing of 
marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana 
production on public lands; (h) Preventing marijuana possession or use on federal property.  Id.; see 
supra note 70. 
 74. Memorandum from Jefferson B. Sessions III, Att’y Gen. on Marijuana Enforcement to All U.S. 
Att’ys (Jan. 4, 2018), https://www.justice.gov/opa/pr/justice-department-issues-memo-marijuana-
enforcement. 
 75. Numerous organizations have advocated for changes related to medical marijuana programs 
including the Marijuana Policy Project and the Drug Policy Alliance. Medical Marijuana, DRUG POL’Y, 
https://drugpolicy.org/issues/medical-marijuana (last accessed Mar. 3, 2021). 
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the specific drug interaction risks posed by marijuana or derivatives such as 
CBD.76  Additionally, marijuana products obtained from dispensaries may only 
be subject to state or local standards for contaminants, manufacturing, storage, 
and packaging, whereas manufacturers of drugs seeking FDA approval must 
adhere to current Good Manufacturing Practices and other FDA requirements.77  
Likewise, marijuana products sold at state-licensed dispensaries have not been 
the subject of clinical research prior to their introduction into commerce, such 
that manufacturers would be able to provide detailed information about a 
product’s risks and benefits and safety considerations for certain populations or 
doses.   
Some health care facilities may have implemented or considered 
implementing policies that permit patient use consistent with the provisions in 
state medical marijuana laws but with limited staff involvement or policies that 
permit patient use, but treat medical marijuana as a self-administered home 
therapy or as medication.78  These policies may address topics such as: (1) 
whether patients are registered medical marijuana patients under state laws; (2) 
confirmation of the illness or condition that would make a patient eligible for a 
medical marijuana program under state law; (3) how the patient may obtain and 
store marijuana (i.e., through a registered caregiver and without health care 
facility employee involvement); (4) administration of the marijuana by the 
patient, a registered caregiver or facility employees; and (5) documentation of 
the marijuana products consumed by the patient.79 
Such policies, while they may comply with state laws, are not without risk.  
Health care providers should review the applicable Medicare Conditions of 
Participation, requirements or conditions for coverage, and related quality 
standards and carefully evaluate the potential risks of creating policies or 
programs that would accommodate such patients or physicians.  Noncompliance 
 
 76. See NATIONAL ACAD. OF SCI., ENG’G, AND MED., THE HEALTH EFFECTS OF CANNABIS AND 
CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH (2017); 
What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis 
or Cannabis-derived Compounds, Including CBD, FDA, https://www.fda.gov/consumers/consumer-
updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-
cannabis (last updated Mar. 05, 2020). 
 77. See, e.g., Colorado Marijuana Rules, COLO. CODE REGS. § 212-3 (2021); 21 C.F.R. § 211. 133 
(2020).  
 78. See, e.g., Medical Marijuana, WASH. HEALTH CARE ASS’N, 
https://www.whca.org/files/2013/04/sample-medical-marijuana-policy.pdf (last accessed Mar. 3, 2021); 
Medical Cannabis Template Policy, MINNESOTA HOSP. ASS’N, (June 17, 2015), 
https://www.mnhospitals.org/Portals/0/Documents/patientsafety/MedCannabis/Medical%20Cannabis%2
0Documentation.pdf (last accessed Mar. 3, 2021). 
 79. Supra note 78. 
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with the Medicare Conditions of Participation or similar requirements may result 
in the termination of Medicare enrollment.80  
For example, even if marijuana use is permissible under state law, hospitals 
must comply with the CSA and other federal laws that criminalize the possession 
and distribution of marijuana, as well as the federal requirements set forth in the 
Medicare Conditions of Participation in order to receive Medicare and Medicaid 
payments.81  The Conditions of Participation require hospitals to comply with 
applicable federal laws related to the health and safety of patients82 and set forth 
several requirements with respect to controlled substances such as marijuana.83  
Drugs must be prepared, controlled, and administered in accordance with federal 
and state laws and applicable standards of practice, which include compliance 
with federal laws, regulations, and guidelines on topics such as recordkeeping, 
security, and reports of abuses and losses of controlled substances.84  All drugs 
must also be administered by or under the supervision of nursing or other 
personnel in accordance with federal and state laws, licensing requirements, and 
approved medical staff policies and procedures.85   
The Conditions of Participation require the maintenance of current and 
accurate records for the receipt and disposition of all scheduled drugs, which 
would include marijuana,86 but hospital and long-term care pharmacists could 
not dispense marijuana without risking violations of their own state licensing 
requirements, the CSA, and federal regulations, such as those that addresses drug 
regimen reviews and unnecessary drugs.87  Pharmacists at hospitals, long-term 
care facilities, and other health care facilities would also be unable to provide 
adequate security for Schedule I controlled substances such as marijuana; current 
regulations impose additional requirements for the storage of Schedule II 
controlled substances but do not contemplate the storage of Schedule I controlled 
substances, which, by definition, have no currently accepted medical use in 
 
 80. 42 C.F.R. § 489.53(a)(3) (2020); see CENTER FOR MEDICARE & MEDICAID SERVS, STATE 
OPERATIONS MANUAL APPENDIX A – SURVEY PROTOCOL, REGULATIONS AND INTERPRETIVE 
GUIDELINES FOR HOSPITALS, INTRODUCTION, Rev. 37 (2020), 
https://www.cms.gov/files/document/som107appendicestoc.pdf [hereinafter STATE OPERATIONS 
MANUAL] (stating that hospitals are required to comply with Medicare Conditions of Participation “in 
order to receive Medicare/Medicaid payment”). 
 81. 42 C.F.R. Part 482 (2020). 
 82. Id. § 482.11(a). 
 83. Id. § 482.25(b). 
 84. Id. §§ 482.25(b), 482.23(c)(1). 
 85. Id. § 482.23(c). 
 86. Id. § 482.25(a)(3). 
 87. See id. § 483.45(d) (stating that each long-term care resident’s drug regimen must be free from 
unnecessary drugs, which would include marijuana because there are no adequate indications for use for 
marijuana). 
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treatment.88  Surveys of hospitals and other facilities, which examine the 
facilities’ compliance with the Conditions of Participation, also include 
inspections of drug storage areas, so any storage of marijuana by a facility could 
lead to a citation for noncompliance.89  The Centers for Medicare & Medicaid 
Services (“CMS”) has stated that any noncompliance with requirements 
regarding pharmaceutical services, including supervised drug storage, must be 
evaluated to determine if a “condition-level” citation is warranted for substantial 
noncompliance with the CMS Conditions of Participation.90  Drug dispensing 
must also be performed consistent with federal laws, such as the federal research 
requirements discussed below in Section IV.91  Further, the Conditions of 
Participation address abuses of controlled substances, which must be reported to 
the individual responsible for pharmaceutical services and to the organization’s 
CEO, as appropriate.92   
As a result, hospitals, long-term care providers, and other facilities that 
must meet the Conditions of Participation or similar requirements should ensure 
that their facilities do not undertake activities that would jeopardize their 
eligibility to participate in Medicare or that would lead to citations for 
noncompliance with federal requirements. 
As health care providers or facilities debate whether to move forward with 
any policies that would comply with state medical marijuana laws, they should 
consider whether their medical malpractice insurance will cover any physician 
recommendation for medical marijuana or any negative outcome that results 
from such a recommendation.93  Physicians should also evaluate any state law 
protections for health care providers who recommend marijuana or the lack of 
such protections.  For example, Massachusetts issued guidance addressing 
penalties and prosecutions under state law for advising a qualifying patient about 
the risks and benefits of medical use of marijuana and providing a qualifying 
 
 88. Id. § 483.45(h). 
 89. See STATE OPERATIONS MANUAL, supra note 80; 42 C.F.R. § 482.25 (2020). 
 90. See STATE OPERATIONS MANUAL, supra note 80, at A-0489. 
 91. 42 C.F.R. § 482.25(b)(1) (2020); see also infra Section IV. 
 92. 42 C.F.R. § 482.25(b)(7) (2020). 
 93. State laws may impose requirements, including a mandate that physicians register as medical 
marijuana providers, and limitations on the types of patients and particular conditions for which medical 
marijuana may be recommended (e.g., AIDS, epilepsy, MS, glaucoma, and neuropathic chronic pain).   
COMMONWEALTH OF MASS., CANNABIS CONTROL COMM’N, GUIDANCE FOR HEALTHCARE PROVIDERS 
REGARDING THE MEDICAL USE OF MARIJUANA (2017), https://www.mass.gov/doc/guidance-for-health-
care-providers-on-the-medical-use-of-marijuana/download.  [hereinafter Mass. Guidance]. State laws 
may also require physicians to have attempted standard medical treatments or offered such treatments to 
patients prior to recommending marijuana. See State Medical Marijuana Laws, NAT’L CONF. OF STATE 
LEGIS. (Jan. 11, 2021), https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx#3. 
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patient with a recommendation for marijuana based on an assessment of the 
patient’s medical history and condition.94 
Health care facilities may also receive questions about policies that address 
the disposal of illegal drugs and smoke-free facilities or drug-free work 
environments.  Polices that prohibit patient possession, self-administration, and 
use would help such facilities ensure compliance with federal requirements.95  
Policies that acknowledge marijuana use by patients participating in FDA 
expanded access programs or clinical trials that are conducted in accordance with 
federal requirements and approved by an Institutional Review Board, but impose 
restrictions on marijuana use in health care facilities, may also ensure compliance 
with federal laws.96  FDA’s expanded access program for marijuana for medical 
use facilitates the availability of investigational products to patients with serious 
diseases or conditions when there is no comparable or satisfactory alternative 
therapy available.97   
IV. MARIJUANA RESEARCH 
Health care facilities may also receive inquiries from physicians and others 
about marijuana research.  Though marijuana dispensaries may be ubiquitous, 
and a facility may be in close proximity to a marijuana dispensary that is licensed 
by the state or locality, in order to conduct research with marijuana, the CSA 
requires a person to register with the DEA and follow ordering, security, and 
other requirements.98  Since research and development conducted in the U.S. 
outside of the CSA’s regulatory scheme could trigger federal civil and criminal 
penalties for the manufacture, distribution, and possession of marijuana, health 
care facilities must ensure that interested researchers adhere to federal 
requirements.99   
 
 94. See Mass. Guidance, supra note 93. 
 95. See, e.g., Mayo Clinic, Medical Marijuana (Nov. 27, 2019), 
https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/medical-marijuana/art-20137855 
(discussing medical cannabis use on Mayo Clinic campuses in Arizona, Florida, and Minnesota). 
 96. See, e.g., Karen Nitkin, New Policy Bars Medical Marijuana Use in Johns Hopkins Facilities, 
JOHNS HOPKINS MED. (May 11, 2018), https://www.hopkinsmedicine.org/office-of-johns-hopkins-
physicians/best-practice-news/new-policy-bars-medical-marijuana-use-in-johns-hopkins-facilities 
(announcing a new policy prohibiting patients from possessing or using medical marijuana in the 
facilities unless the patient is part of a clinical trial approved by the institutional review board). 
 97. FDA and Cannabis: Research and Drug Approval Process, FDA (2021), 
https://www.fda.gov/newsevents/publichealthfocus/ucm421163.htm. 
 98. 21 U.S.C. §§ 822, 823(f).  DEA regulations govern orders for Schedule I controlled substances.   
21 C.F.R. § 1305.06 (2020). 
 99. 21 U.S.C. §§ 841, 844.  The CSA also provides for criminal forfeiture of property and proceeds 
derived from a violation of the CSA and civil forfeiture of property including equipment, money, 
records, research, and property used or intended to be used to violate the CSA.  Id. §§ 853, 881.  The 
CSA provides that any person who attempts or conspires to commit an offense under the Act is subject 
to the same penalties as those prescribed for the offense.  Id. § 846. 
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The CSA makes it a federal crime to cultivate, possess, and distribute 
marijuana and other Schedule I drugs, except under limited exceptions for 
federally-approved research and the cultivation of marijuana for legitimate 
researchers.100  The CSA enables research pertaining to medical uses and the 
development of new drugs, as opposed to research for purposes such as the 
commercial development of marijuana or THC products.101  The CSA and related 
DEA regulations also govern providers and researchers interested in growing 
marijuana for their own studies.102  The CSA prohibits human consumption of 
any quantity of a Schedule I controlled substance except during clinical research 
approved by FDA and conducted by a DEA-registered researcher.103   
The Secretary of the U.S. Department of Health and Human Services 
(“HHS”) must determine the qualifications and competency of each practitioner 
seeking to register with the DEA, as well as the merits of the research protocol.104  
When determining if a research protocol has merit, the Secretary of HHS must 
consult with the Attorney General regarding procedures to adequately safeguard 
against diversion from legitimate medical or scientific use.105  The Attorney 
General can then deny a practitioner’s registration under certain grounds, such 
as a felony conviction related to a controlled substance.106  As of June 2020, there 
are 589 registered Schedule I researchers who have obtained DEA registrations 
to conduct research on marijuana, marijuana extracts, and marijuana 
derivatives.107   
DEA-registered marijuana researchers receive supplies through the 
National Institute on Drug Abuse (“NIDA”) Drug Supply Program from the sole 
federally authorized marijuana grower, the University of Mississippi, which 
coordinates with law enforcement agencies on the transportation of marijuana.108  
The CSA and DEA policies limit the growth of marijuana for research purposes 
 
 100. Id. §§ 822, 841, 842. 
 101. Id. §§ 822, 823, 828, 872(e). 
 102. Controls to Enhance the Cultivation of Marihuana for Research in the United States, 85 Fed. 
Reg. 82333, 82336 (Dec. 18, 2020) (to be codified at 21 C.F.R. pts. 1301 and 1318). 
 103. 21 U.S.C. § 811, 812, 823(f); United States v. Oakland Cannabis Buyers’ Cooperative, 532 
U.S. 483, 490 (2001); 21 C.F.R. §§ 1301.18, 1301.32 (2020). 
 104. 21 U.S.C. § 823(f).  Practitioners include physicians, scientific investigators or other persons 
licensed, registered or otherwise permitted by the U.S. or the jurisdiction in which the practitioner 
practices or does research, to distribute, dispense, or conduct research with respect to a controlled 
substance in the course of professional practice or research.  Id. § 802(21). 
 105. Id. § 823(f). 
 106. Id. § 824(a). 
 107. Controls to Enhance the Cultivation of Marihuana for Research in the United States, 85 Fed. 
Reg. 82333, 82336 (Dec. 18, 2020) (to be codified at 21 C.F.R. pts. 1301 and 1318).   
 108. NIDA Drug Supply Program, NAT’L INST. ON DRUG ABUSE (June 27, 2017), 
https://www.drugabuse.gov/research/research-data-measures-resources/nida-drug-supply-program. 
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through registration requirements and production quotas.109  Registrations of 
marijuana growers must be consistent with the public interest—which is 
determined based on factors such as compliance with state law and effective 
controls against diversion—as well as U.S. treaty obligations under the 1961 
international Single Convention on Narcotic Drugs (“Single Convention”).110   
Under the Obama Administration, the DEA issued a policy aimed at 
increasing the number of authorized growers in order to meet researcher demand 
for marijuana and CBD extracts.111  The 2016 policy would have permitted 
persons to register with DEA to grow marijuana for researchers as well as 
“strictly commercial endeavors funded by the private sector and aimed at drug 
product development.”112  The increased number of growers registered by DEA 
would have remained limited, as a statute requires that the manufacture be 
conducted by a number of establishments which can produce an adequate and 
uninterrupted supply of the controlled substance under adequately competitive 
conditions for legitimate medical, scientific, research, and industrial purposes.113  
DEA received approximately 38 applications as a result of the 2016 policy 
statement; as of December 18, 2020, all applications are pending.114 
In December 2020, the DEA issued a final rule to facilitate the cultivation 
of marijuana for research and other legal purposes, which became effective on 
the last full day of the Trump Administration.115  The rule was drafted to ensure 
compliance with U.S. obligations under the Single Convention and the CSA.116  
The rule states that DEA anticipates approving more than one person to cultivate 
and harvest bulk marijuana.117  The Biden Administration may re-examine this 
final rule, which does not address the cultivation of marijuana for commercial 
endeavors, as well as a separate set of U.S. Department of Agriculture regulations 
governing the commercial production of industrial hemp.118 
 
 109. 21 U.S.C. §§ 822, 826. 
 110. Id. § 823(a); Controls to Enhance the Cultivation of Marihuana for Research in the United 
States, 85 Fed. Reg. 16292, 16294 (Mar. 23, 2020) (to be codified at 21 C.F.R. pts. 1301, 1318). 
 111. Applications to Become Registered Under the [CSA] to Manufacture Marijuana to Supply 
Researchers in the [U.S.], 81 Fed. Reg. 53846, 53848 (Aug. 12, 2016). 
 112. Id. 
 113. 21 U.S.C. § 823(a). 
 114. Controls to Enhance the Cultivation of Marihuana for Research in the United States, 85 Fed. 
Reg. 82333, 82347 (Dec. 18, 2020) (to be codified at 21 C.F.R. pts. 1301 and 1318). 
 115. Id.  Since the rule took effect before January 20, 2021, it does not appear to be subject to 
President Biden’s regulatory freeze on last-minute regulations issued by the Trump Administration.   
Memorandum for the Heads of Executive Departments and Agencies, Regulatory Freeze Pending 
Review (Jan. 20, 2021), https://www.whitehouse.gov/briefing-room/presidential-
actions/2021/01/20/regulatory-freeze-pending-review/ [hereinafter Regulatory Freeze Memorandum]. 
 116. 85 Fed. Reg. at 82339. 
 117. Id. at 82436–37. 
 118. Establishment of a Domestic Hemp Production Program, 86 Fed. Reg. 5596 (Jan. 19, 2021) (to 
be codified at 7 C.F.R. pt. 990).  These regulations are subject to the regulatory freeze order because the 
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V. CONCLUSION 
Federal regulation of cannabis is evolving rapidly.  The Biden 
Administration will undoubtedly seek to advance new laws and implement new 
regulations and policies consistent with President Biden’s own priorities.  Health 
care facilities and providers should monitor proposed congressional legislation, 
congressional hearings, DEA and FDA rulemakings, and DOJ, DEA, and FDA 
guidance in this evolving area of law to avoid any pitfalls and unnecessary risks.  
To understand the full scope of permissible and impermissible activities, health 
care facilities and providers should seek counsel with experience with federal 
marijuana laws, food and drug laws, and hemp laws.  State marijuana laws and 
regulations cannot insulate health care entities from liability under federal law, 
including liability for aiding and abetting violations of the CSA or conspiring to 
violate the CSA.  Future congressional legislation and executive branch 
proposals may address such matters, but until any changes in federal law occur, 
health care entities must take care to ensure that their operations fully comply 
with applicable cannabis laws. 
 
 
effective date was initially March 22, 2021.  Regulatory Freeze Memorandum, supra note 115.  As a 
result, the regulations may be postponed, modified, withdrawn or subject to other actions by the Biden 
Administration.  Id. 
